Peer-influenced content. Sources you trust. No registration required. This is HCN.
Drug Policy Alliance
Here’s everything you could possibly want to know about “magic” mushrooms, including their short- and long-term effects on people, risks, history, and much more.
Clinical Pharmacology August 5th 2022
MDLinx
Kar-XT adds trospium to xanomeline to substantially improve the second agent’s tolerability, enabling its use to reduce both positive and negative symptoms in schizophrenia. Allopregnanolone, an oral version of brexanolone, is being investigated in MDD. The dextromethorphan and bupropion combo, AXS-05, seeks to offer a new antidepressant option and hydroxynorketamine promises MDD treatment without ketamine’s dissociative effects and abuse potential.
Psychiatry August 2nd 2022
JAMA Network
In 2021, melatonin was the most frequently reported substance involved in pediatric substance ingestions, resulting in 4,000 hospitalizations, 287 ICU admissions, and 2 deaths in children under the age of 2. Melatonin supplements can have 500% more melatonin than indicated on the label and about 30% of OTC products tested had serotonin as well.
Emergency Medicine July 19th 2022
Psychiatry Advisor
Using covariate analysis of records from more than 1.2 million children over 17 years, these researchers conclude that the elevated risk for neonatal seizures and childhood epilepsy in children who were exposed to SSRIs or SNRIs during pregnancy can be attributed to the indicated SSRI and SNRI use for pregnant women, history of parental epilepsy, and other covariates, rather than the use of the medication itself.
Obstetrics & Gynecology July 19th 2022
Selecting effective antidepressants for the treatment of major depressive disorder is an imprecise practice. With remission rates of about 30% after the initial therapy selection, there is a need to uncover biomarkers able to predict treatment response. This study looked at pharmacogenomic testing for drug-gene interactions to guide treatment selection. Unfortunately, they did not find significantly improved outcomes.
Psychiatry July 19th 2022
Medical Professionals Reference (MPR)
The Emergency Use Authorization (EUA) for Paxlovid has been revised to reflect the new prescribing authority given to state-licensed pharmacists. Under this revision, patients must now show health records within the last year, which needs to include bloodwork, as well as a list of their current medications, including any over-the-counter (OTC).
All Specialties July 13th 2022